FKONCO

Fresenius Kabi Oncology Limited has informed the Exchange that "In continuation to our earlier letter, dated April 17, 2013, please be informed that the Company has obtained requisite shareholders' approval through Postal Ballot on the Special Resolution for delisting of the equity shares of the Company from the stock exchanges in accordance with the SEBI (Delisting of Equity Shares) Regulations, 2009, as specified in the notice of Postal Ballot dated April 17, 2013, read with explanatory statement attached thereto".

Fresenius Kabi Oncology Limited has submitted to the Exchange vide letter dated April 23, 2013 a copy of notice of Postal Ballot pursuant to Section 192A(2) of the Companies Act, 1956 read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2011 together with Explanatory Statement of the Postal Ballot being conducted by the Company to transact the following business: (1) Special Resolution regarding voluntarily delisting of the equity shares of the Company from the stock exchanges in accordance with the SEBI (Delisting of Equity Shares) Regulations, 2009.

Fresenius Kabi Oncology Limited has informed the Exchange that the Company has obtained requisite Shareholders approval through Postal Ballot, pursuant to Section 192A of the Companies Act, 1956 on the Special Resolution for appointment of Mr. Peter F. Nilsson as the Managing Director & CEO of the Company w.e.f. October 20, 2011 for a period of two years.

Fresenius Kabi Oncology Limited has submitted to the Exchange a copy of notice pursuant to Section 192A of the Companies Act, 1956 read with the Companies (Passing of Resolution by Postal Ballot) Rules, 2011, in respect of the resolution to be passed through Postal Ballot : Special Resolution for appointment of Mr. Peter F. Nilsson as the Managing Director & CEO of the Company.

Fresenius Kabi Oncology Limited has informed the Exchange regarding the outcome of Annual General Meeting of the Company held on July 29, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/FRESENIUS_OAGM_30072009.zip target=NEW> For more details click here.</a>

Fresenius Kabi Oncology Limited has submitted to the Exchange a copy of Notice of the Annual General Meeting of the Shareholders of the Company to be held on July 29, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Fresenius_AGM_07072009.zip target=NEW> For more details click here.</a>

Fresenius Kabi Oncology Limited has informed the Exchange that at the Extra-Ordinary General Meeting of the Company held on March 13, 2009, the shareholders have accorded consent to the Board of Directors of the Company to offer, issue and allot 1550255 number of equity shares of the Company, constituting 0.99% of the pre-issue (existing) issued and paid up share capital of the Company ("Shares") to Atlas- Vermoegensverwaltungs- GmbH, on a preferential basis, in such manner and on such other terms and conditions as may be determined by the Board of Directors in its absolute discretion at a pri

Dabur Pharma Limited has submitted to the Exchange a copy of the Notice along with Explanatory Statement of the Extra Ordinary General Meeting to be held on March 13, 2009 to transact the Special business mentioned in the Notice. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/daburpharma_NOTEGM_17022009.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that the Board of Directors of the Company by way of circular resolutions passed on February 12, 2009 has :(1) Subject to receipt of shareholders' consent and other applicable regulatory approvals, approved the offer and issue of 15,50,255 number of equity shares of the Company constituting 0.99% of the pre-issue (existing) issued and paid up share capital of the Company ("Shares") to Atlas-ermoegensverwaltungs-GmbH, on a preferential basis at a price determined in accordance with the SEBI (Disclosure and Investor Protection) Guidelines, 2000. (2)

Dabur Pharma Limited has informed the Exchange that :"The Company has obtained requisite Shareholders approval through Postal Ballot pursuant to Section 192A of the Companies Act, 1956 on the Special resolution for change of name of the company from "Dabur Pharma Limited" to "Fresenius Kabi Oncology Limited" pursuant to Section 21 and other applicable provisions of the Companies Act, 1956".

Dabur Pharma Limited has informed the Exchange that Pursuant to the provisions of Section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, the Company is seeking the consent of its members through Special Resolution proposed to be passed by Postal Ballot in respect of Special resolution for change of name of the Company from Dabur Pharma Limited to Fresenius Kabi Oncology Limited. The Company has appointed Ms. Kiran Sharma, Practicing Company Secretary as the Scrutinizer for conducting the postal ballot process. The duly complete

Dabur Pharma Limited has informed the Exchange that the Company has obtained requisite Shareholders approval through Postal Ballot pursuant to Section 192A of the Companies Act, 1956 on the Ordinary resolution for appointment and remuneration of Dr. Satish Kulkarni as the Managing Director and CEO of the Company w.e.f. August 11, 2008 for a period of five years.

Dabur Pharma Limited has informed the Exchange that pursuant to the provision of Section 192A of the Companies Act, 1956, read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, the Company is seeking the consent of its members through postal ballot for the following : 1) Ordinary Resolution for appointment and terms and conditions of Dr. Satish Kulkarni as Managing Director & CEO of the Company. The Company has appointed Ms. Kiran Sharma, Practicing Company Secretary as the Scrutinizer for conducting the Postal Ballot process. The Company has appointed Mr. Rakesh Bha

Dabur Pharma Limited has informed the Exchange regarding the outcome of Annual General Meeting held on July 21, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DabarPharma_OutAGM_22072008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that : "The Company has obtained requisite Shareholders approval through Postal Ballot pursuant to Section 192A of the Companies Act, 1956 on the Special resolution for cancellation of 1481226 employees Stock Options granted to five eligible employees and option to other employees to surrender their outstanding options/shadow options".

Dabur Pharma Limited has informed the Exchange that pursuant to the provision of Section 192A of the Companies Act, 1956, read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, the Company is seeking the consent of its members through Special Resolution proposed to be passed by Postal Ballot in respect of the following Special Business: 1) Special resolution for cancellation of 1481226 outstanding Employee Stock Options and providing an option to the other employees to surrender their outstanding options/ shadow options. The Company has appointed Ms. Kiran Sharma, Pr

Dabur Pharma Limited has submitted to the Exchange a copy of the Minutes of the Annual General Meeting of the Company held on July 25, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DABUR_AGM_270807.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that the Annual General Meeting of the Company has been convened on July 25, 2007 wherein following resolutions have been passed: 1) Dr. Anand C Burman, Mr. P D Narang and Dr. Naresh Trehan, Directors of the Company have been re-appointed as directors liable to retire by rotation. 2) Mr. Ashok Vij has been appointed as Director of the Company. 3) M/s. G Basu & Co. Chartered Accountants, has been re-appointed as auditors to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting. 4) M/s

Dabur Pharma Limited has submitted to the Exchange a copy of the Notice of Annual General Meeting of the members of the Company scheduled to be held on July 25, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DaburPharma_AGMNotice.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that: "The Company has obtained requisite Shareholders approval through Postal Ballot pursuant to Section 192A of the Companies Act, 1956 on the Ordinary resolution regarding sale of non-oncology formulations division of the Company under Section 293(1)(a) of the Companies Act, 1956".

Dabur Pharma Limited has informed the Exchange that pursuant to Section 192A of the Companies Act, 1956, read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, the Company is seeking the shareholders' consent to the following Ordinary Resolution, proposed to be passed by Postal Ballot: Ordinary Resolution for sale of 'Non Oncology Formulations Division' of the Company under Section 293 (1) (a) of the Companies Act, 1956. The Board of Directors has appointed Mr. T R Ramamurthy, Practicing Company Secretary as the Scrutinizer, for conducting the postal ballot process.

Dabur Pharma Limited has informed the Exchange that the Shareholders of the company at the AGM held on July 14,2006 unanimously approved all the agenda items contained in the Notice convening the said meeting except the resolution at agenda item no.11 of the notice regarding approval under Sections 81 (1A) of the Companies Act, 1956 for issue of securities in any currency up to USD 25 Million. This resolution was dropped as the shareholders felt that the timing, quantum and the pricing of the issue was not in the best interests of the Company.

Dabur Pharma Limited has submitted to the Exchange a copy of the notice of AGM of the members of the Company scheduled to be held on July 14, 2006. A copy of the notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Dabur Pharma Limited has informed the Exchange that at the AGM of the Company held on July 26, 2005, the shareholders of the Company unanimously approved all the resolutions mentioned in the Agenda Notice circulated to all the shareholders of the Company including the following: (1) declared a dividend of 10% (Re.0.10 per share) for the FY ended March 31, 2005; (2) approved appointment of Dr. Naresh Trehan as Director of the Company, and (3) approved all the amendments to Articles of Association of the Company, as proposed.

Dabur Pharma Limited has submitted to the Exchange a copy of the proceedings at the EGM of the Company held on May 30, 2005. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Dabur Pharma Limited has informed the Exchange of the outcome of the EGM of the company held on May 30,2005:1)The shareholders unanimously approved issue of equity shares on preferential basis to International Finance corporation and to Dabur Research Foundation Employees Trust, and 2)Unanimously approved amendment to capital clause of the memorandum of association of the company.

Dabur Pharma Limited has informed the Exchange that an EGM of the members of the Company will be held on May 30, 2005. The details of the EGM notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).